Growth Metrics

bioAffinity Technologies (BIAF) Cash from Operations (2021 - 2026)

bioAffinity Technologies has reported Cash from Operations over the past 5 years, most recently at 3227240.0 for Q1 2026.

  • Quarterly Cash from Operations fell 96.57% to 3227240.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 10914307.0 through Mar 2026, down 66.36% year-over-year, with the annual reading at 9328842.0 for FY2025, 28.41% down from the prior year.
  • Cash from Operations was 3227240.0 for Q1 2026 at bioAffinity Technologies, down from 2559563.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 376141.0 in Q2 2022 and troughed at 3227240.0 in Q1 2026.
  • The 5-year median for Cash from Operations is 1641775.0 (2025), against an average of 1760560.47.
  • Year-over-year, Cash from Operations tumbled 261.55% in 2023 and then skyrocketed 30.02% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 1300636.0 in 2022, then fell by 24.27% to 1616303.0 in 2023, then decreased by 3.77% to 1677161.0 in 2024, then tumbled by 52.61% to 2559563.0 in 2025, then decreased by 26.09% to 3227240.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Cash from Operations are 3227240.0 (Q1 2026), 2559563.0 (Q4 2025), and 2480298.0 (Q3 2025).